250 related articles for article (PubMed ID: 12210870)
21. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.
Wu J; Tang T; Bezprozvanny I
Neurosci Lett; 2006 Oct; 407(3):219-23. PubMed ID: 16959411
[TBL] [Abstract][Full Text] [Related]
22. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.
Turmaine M; Raza A; Mahal A; Mangiarini L; Bates GP; Davies SW
Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8093-7. PubMed ID: 10869421
[TBL] [Abstract][Full Text] [Related]
23. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.
Keene CD; Rodrigues CM; Eich T; Chhabra MS; Steer CJ; Low WC
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10671-6. PubMed ID: 12149470
[TBL] [Abstract][Full Text] [Related]
24. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
25. Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.
Estrada-Sánchez AM; Burroughs CL; Cavaliere S; Barton SJ; Chen S; Yang XW; Rebec GV
J Neurosci; 2015 Mar; 35(10):4440-51. PubMed ID: 25762686
[TBL] [Abstract][Full Text] [Related]
26. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.
Menalled LB; Sison JD; Wu Y; Olivieri M; Li XJ; Li H; Zeitlin S; Chesselet MF
J Neurosci; 2002 Sep; 22(18):8266-76. PubMed ID: 12223581
[TBL] [Abstract][Full Text] [Related]
27. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice.
Meade CA; Deng YP; Fusco FR; Del Mar N; Hersch S; Goldowitz D; Reiner A
J Comp Neurol; 2002 Jul; 449(3):241-69. PubMed ID: 12115678
[TBL] [Abstract][Full Text] [Related]
28. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene.
Hansson O; Guatteo E; Mercuri NB; Bernardi G; Li XJ; Castilho RF; Brundin P
Eur J Neurosci; 2001 Nov; 14(9):1492-504. PubMed ID: 11722611
[TBL] [Abstract][Full Text] [Related]
29. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
Hansson O; Petersén A; Leist M; Nicotera P; Castilho RF; Brundin P
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8727-32. PubMed ID: 10411943
[TBL] [Abstract][Full Text] [Related]
30. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.
Cowin RM; Roscic A; Bui N; Graham D; Paganetti P; Jankowsky JL; Weiss A; Paylor R
Behav Brain Res; 2012 Apr; 229(2):308-19. PubMed ID: 22306231
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus.
Lüesse HG; Schiefer J; Spruenken A; Puls C; Block F; Kosinski CM
Behav Brain Res; 2001 Nov; 126(1-2):185-95. PubMed ID: 11704263
[TBL] [Abstract][Full Text] [Related]
32. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
33. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
Brown TB; Bogush AI; Ehrlich ME
Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
[TBL] [Abstract][Full Text] [Related]
34. Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice.
Kosinski CM; Cha JH; Young AB; Mangiarini L; Bates G; Schiefer J; Schwarz M
Neuroreport; 1999 Dec; 10(18):3891-6. PubMed ID: 10716229
[TBL] [Abstract][Full Text] [Related]
35. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
36. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.
Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP
Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988
[TBL] [Abstract][Full Text] [Related]
37. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.
Murphy KP; Carter RJ; Lione LA; Mangiarini L; Mahal A; Bates GP; Dunnett SB; Morton AJ
J Neurosci; 2000 Jul; 20(13):5115-23. PubMed ID: 10864968
[TBL] [Abstract][Full Text] [Related]
38. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
39. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
Becher MW; Kotzuk JA; Sharp AH; Davies SW; Bates GP; Price DL; Ross CA
Neurobiol Dis; 1998 Apr; 4(6):387-97. PubMed ID: 9666478
[TBL] [Abstract][Full Text] [Related]
40. Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.
Buren C; Parsons MP; Smith-Dijak A; Raymond LA
Neurobiol Dis; 2016 Mar; 87():80-90. PubMed ID: 26711622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
